Thermo Fisher Scientific Daclizumab Chimeric Recombinant Rabbit Monoclonal Antibody (Daclizumab)

Applications

Flow Cytometry (Flow)

• Tested Dilution: 1 µg/mL

Inhibition Assays (IA)

• Tested Dilution: Assay-dependent

Product Specifications

Product Specific Information

Specificity: Binds to p55 chain of IL2R on human T cells (Tac antigen), which is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.

Target Information

Humanized IgG1 monoclonal antibody that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25).
Daclizumab is composed of approximately 90% human and 10% murine antibody sequences.

• Human sequences: Derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.
• Murine sequences: Derived from the complementarity-determining regions of a murine anti-Tac antibody.

On April 22, 2008, Roche Registration Limited voluntarily withdrew the marketing authorization for Zenapax (daclizumab), indicated for prophylaxis of acute organ rejection in renal transplantation, for commercial reasons unrelated to safety.
Biogen and Abbvie’s Zinbryta (daclizumab) was later approved by the FDA in 2016 for treatment of adult patients with relapsing forms of multiple sclerosis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.